Kardigan (KARD) investor relations material

Company overview and strategy

• Focuses on addressing root causes of major cardiovascular diseases with a platform approach, leveraging new technologies and adaptive trial designs to accelerate development and improve outcomes.

• Robust late-stage pipeline targets dilated cardiomyopathy, aortic stenosis, and acute severe hypertension, aiming for disease-modifying therapies.

• Utilizes the Prolaio platform, integrating real-world and continuous patient data from wearables and EMRs, enhancing trial enrichment and patient profiling.

• Emphasizes synergies across programs and portfolio de-risking, with expertise in portfolio management and resource allocation.

• Plans to share pivotal data and advance toward commercialization by the first half of 2027.

Advances in genetic cardiomyopathy (danicamtiv)

• Danicamtiv targets genetic dilated cardiomyopathy by improving myosin head engagement, restoring contractility, and promoting reverse remodeling.

• Benefits observed across multiple cardiac chambers, including improvements in left and right ventricular function and reductions in arrhythmic risk.

• Phase IIb/III adaptive seamless trial (KINSHIP-DCM) is enrolling, with early open-label data informing phase III; primary endpoints include echo parameters and peak VO2.

• Adaptive design allows for early data review and sample size adjustments, aiming for a clinically meaningful improvement in peak VO2.

• Enrollment for phase IIb Cohort 1 is complete, with phase III enrollment ongoing for myosin and titin gene variant patients.

Innovations in aortic stenosis (ataciguat)

• Ataciguat, an oral sGC activator, is being developed for moderate aortic stenosis, targeting both valve calcification and ventricular function.

• Mechanism increases cyclic GMP in the valve and ventricle, reducing calcium deposition and improving cardiac function without systemic hypotension.

• Clinical benefit is linked to improvements in valve area and cardiac function, with potential for life cycle expansion across the disease continuum.

• Phase IIb trial is enrolling, with interim data on valve calcium and echo measures expected in the first half of next year and primary analysis at 48 weeks.

• Long-term vision includes slowing disease progression and reducing the need for repeat interventions as patients age.